Suppr超能文献

因院前直接口服抗凝治疗而入院的重症监护病房患者的抗凝处方模式:单学术中心经验

Anticoagulation Prescribing Patterns in Intensive Care Unit Patients Admitted with Prehospital Direct Oral Anticoagulant Therapy: A Single Academic Center Experience.

作者信息

Lal Amos, Mukhtar Osama, Chalmers Sarah J, Karp John, Wieruszewski Patrick M, Park John G

机构信息

Mayo Clinic, Rochester, MN, USA.

Royal College of Surgeons, Dublin, Ireland.

出版信息

Hosp Pharm. 2023 Feb;58(1):84-91. doi: 10.1177/00185787221122656. Epub 2022 Sep 4.

Abstract

OBJECTIVE

To describe the current prescribing practices of direct oral anticoagulants (DOACs) in intensive care unit (ICU) patients and the associated clinical outcomes, including the incidence of major bleeding episodes and the need for intervention (endoscopic, surgical, or interventional radiology guided).

DESIGN

Observational, retrospective chart review.

SETTING AND PARTICIPANTS

Single large academic center study. Participants included patients with critical illness who were admitted to the intensive care units (ICU) at Mayo Clinic from January 1st, 2012, until May 4th, 2018. Adult ICU patients with a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) listed as one of the active medications at the time of hospital admission were included.

RESULTS

37 249 patients in medical and surgical intensive care units were screened for the study period. After excluding patients who did not qualify, 558 unique encounters were included. The median age was 69 (IQR 59-78) years; most patients were male, white Caucasians, and had a median SOFA score of 4. After excluding the patients who had major bleeding episodes in the first 24 hours, 188 (39%) were continued on the same DOAC therapy, 204 (42%) were discontinued without transitioning to another agent, and 95 (20%) were transitioned to another agent. Finally, 410 (84%) were dismissed on DOAC therapy at the end of hospitalization. The difference in the continuation rate of the same DOAC agent beyond 24 hours, discontinuation without transition to an alternate agent, or discontinuation of DOAC with a transition to an alternate anticoagulation agent was not statistically significant ( = .60). A total of 52 major bleeding events were identified. Gastrointestinal bleeding was the most common bleeding complication [n (%): 34 (65)], followed by intra-abdominal and peri-procedural bleeding [7 (13.5) and 7 (13.5)]. Thirty-three (65%) patients had a major bleeding complication requiring intervention.

CONCLUSIONS

Our single-center retrospective study describes the current prescribing practices and preliminary outcomes in ICU patients with prehospital use of DOACs. Up to 20% of the patients were transitioned to a different agent within 24 hours of ICU admission, whereas a significant proportion of patients (42%) had anticoagulation discontinued altogether. Most patients who suffered a major bleeding episode required either endoscopic or surgical intervention to control bleeding.

摘要

目的

描述重症监护病房(ICU)患者直接口服抗凝剂(DOACs)的当前处方实践及相关临床结局,包括大出血事件的发生率以及干预需求(内镜、手术或介入放射学引导下的干预)。

设计

观察性、回顾性病历审查。

设置与参与者

单一大型学术中心研究。参与者包括2012年1月1日至2018年5月4日期间入住梅奥诊所重症监护病房(ICU)的危重症患者。纳入在入院时将DOAC(阿哌沙班、利伐沙班、达比加群或依度沙班)列为活性药物之一的成年ICU患者。

结果

在研究期间对37249名内科和外科重症监护病房患者进行了筛查。排除不符合条件的患者后,纳入了558例独特病例。中位年龄为69岁(四分位间距59 - 78岁);大多数患者为男性、白种人,中位序贯器官衰竭评估(SOFA)评分为4分。排除在最初24小时内发生大出血事件的患者后,188例(39%)继续使用相同的DOAC治疗,204例(42%)停药且未转换为其他药物,95例(20%)转换为其他药物。最终,410例(84%)患者在住院结束时继续接受DOAC治疗。24小时后相同DOAC药物的继续使用率、未转换为替代药物而停药或停用DOAC并转换为替代抗凝药物之间的差异无统计学意义(P = 0.60)。共确定了52例大出血事件。胃肠道出血是最常见的出血并发症[n(%):34(65)],其次是腹腔内和围手术期出血[7(13.5)和7(13.5)]。33例(65%)患者发生大出血并发症需要干预。

结论

我们的单中心回顾性研究描述了ICU患者院前使用DOACs的当前处方实践和初步结局。高达20%的患者在入住ICU后24小时内转换为不同药物,而相当比例的患者(42%)完全停用了抗凝药物。大多数发生大出血事件的患者需要内镜或手术干预来控制出血。

相似文献

4
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.综述文章:直接口服抗凝剂与胃肠道出血风险
Cardiovasc Drugs Ther. 2022 Oct;36(5):973-989. doi: 10.1007/s10557-021-07211-0. Epub 2021 Jun 18.

本文引用的文献

7
Is there a role for low-dose DOACs as prophylaxis?低剂量 DOAC 作为预防措施是否有作用?
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):187-193. doi: 10.1182/hematology.2019000026.
8
Direct-Acting Oral Anticoagulants in Critically Ill Patients.直接口服抗凝剂在危重症患者中的应用。
Chest. 2019 Sep;156(3):604-618. doi: 10.1016/j.chest.2019.05.025. Epub 2019 Jun 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验